Talphera appoints Joseph Todisco (CorMedix CEO) to board; grants RSUs and options

TALPHERA, INC.

Joseph Todisco appointed Class III director and compensation committee member effective Oct 14, 2025.
Todisco is CEO of CorMedix; appointment per Sept 2025 securities purchase agreement.
Granted 6,397 RSUs and options for 38,381 shares at $1.11, vesting in three equal annual installments.
CorMedix retains right to designate one board member while holding >=25% of shares from private placement.
CorMedix gets 60-day exclusive right to negotiate acquisition of Talphera after Niyad NEPHRO CRRT results, until Dec 31, 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.